Adial Pharmaceuticals (ADIL)
(Delayed Data from NSDQ)
$1.73 USD
+0.02 (1.17%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $1.74 +0.01 (0.58%) 7:58 PM ET
4-Sell of 5 4
F Value B Growth B Momentum D VGM
Income Statements
Fiscal Year end for Adial Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 7 | 13 | 19 | 11 | 8 |
Income After Depreciation & Amortization | -7 | -13 | -19 | -11 | -8 |
Non-Operating Income | 0 | 1 | 0 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -7 | -13 | -20 | -11 | -9 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -7 | -13 | -19 | -11 | -9 |
Extras & Discontinued Operations | 2 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -5 | -13 | -19 | -11 | -9 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -7 | -13 | -19 | -11 | -8 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -7 | -13 | -19 | -11 | -8 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 1.43 | 1.00 | 0.74 | 0.50 | 0.39 |
Diluted EPS Before Non-Recurring Items | -4.91 | -12.75 | -26.00 | -21.75 | -21.75 |
Diluted Net EPS (GAAP) | -3.60 | -12.75 | -26.00 | -21.75 | -21.75 |
Fiscal Year end for Adial Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 1.13 | 1.36 | 1.48 | 2.92 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -1.13 | -1.36 | -1.48 | -2.92 |
Non-Operating Income | NA | -0.11 | 0.01 | -0.03 | 0.01 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -1.24 | -1.35 | -1.51 | -2.91 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -1.24 | -1.35 | -1.51 | -2.91 |
Extras & Discontinued Operations | NA | -0.68 | -0.04 | 2.60 | 0.00 |
Net Income (GAAP) | NA | -1.92 | -1.38 | 1.09 | -2.91 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | NA | 1.18 | 1.13 | 1.06 |
Diluted EPS Before Non-Recurring Items | NA | NA | -1.14 | -1.33 | -2.75 |
Diluted Net EPS (GAAP) | NA | -0.63 | -1.18 | 0.96 | -2.75 |